A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RGT-264 Phosphate Tablets in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05764915
• Other study ID #: RGT-264-101
• Secondary ID: CTR20223017
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 15, 2023
• Est. completion date: August 2, 2025

Study information

• Verified date: January 2024
• Source: Regor Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RGT-264 as monotherapy in subjects with advanced solid tumors.

Description:

This first-in-human (FIH) study of RGT-264 will evaluate safety, pharmacokinetics (PK) and efficacy of RGT-264 in subjects with advanced solid tumors. The primary objective is to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D) of RGT-264 as monotherapy, and to evaluate the safety and tolerability of RGT-264. The secondary objectives include the assessments of PK profile and preliminary efficacy of RGT-264.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 56
• Est. completion date: August 2, 2025
• Est. primary completion date: February 20, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Able to sign the ICF and agree to comply with the requirements of the study;

• Subjects with pathologically confirmed advanced solid tumors who have failed standard-of-care therapy, or have no standard-of-care therapy available, or are currently not eligible for standard-of-care therapy;

• ECOG performance status score of 0 to 1;

• Expected survival = 3 months;

• With at least one measurable lesion per RECIST v1.1;

• Subjects should discontinue all anti-tumor therapies prior to receiving study treatment, and the toxicity caused by prior anti-tumor therapy has recovered to = Grade 1 per CTCAE v5.0;

• The specific requirements of washout period should be met before first dose;

• Adequate organ function

• Female subjects of childbearing potential must have a negative pregnancy test prior to the first dose and are required to use effective contraception from signing the ICF until 6 months after the last dose of study treatment

Exclusion Criteria:

• Presence of risks that may significantly affect the absorption of the investigational product (e.g. inability to swallow, intestinal obstruction, chronic diarrhea, etc.);

• Having received immunotherapy and experienced = Grade 3 immune-related adverse events (irAEs) or = Grade 2 immune-related myocarditis;

• Having received systemic glucocorticoids (> 10 mg/day of prednisone or equivalent) or other immunosuppressants within 14 days prior to the first dose of investigational product;

• Presence of symptomatic parenchymal brain metastasis or leptomeningeal metastasis;

• Active, or previous autoimmune disease with the potential for relapse (excluding well-controlled type 1 diabetes mellitus; manageable hypothyroidism with hormone replacement therapy only).;

• Any other malignancy (except cured basal cell carcinoma of skin and in-situ carcinoma of the cervix) within 3 years prior to the first dose;

• History of serious cardiovascular and cerebrovascular diseases;

• Presence of active interstitial lung disease or history of interstitial lung disease requiring glucocorticoid treatment;

• Presence of severe chronic or active infections (including tuberculosis infection, etc.) requiring intravenous antimicrobial, antifungal or antiviral therapy;

• Active HBV or HCV infection;

• History of immunodeficiency or organ transplantation;

• Presence of uncontrolled third spacing fluid;

• Concomitant diseases or any other conditions that may seriously jeopardize the subject's safety or affect the subject's completion of the study, at the discretion of the investigator.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• RGT-264 phosphate tablets
RGT-264 phosphate tablets will be administered orally once daily (QD).

Locations

Country	Name	City	State
China	Shandong Provincial Institute of Cancer Prevention and Treatment	Jinan	Shandong
China	The First Affiliated Hospital Of Nanchang University City	Nanchang	Jiangxi
China	Shanghai East Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Regor Pharmaceuticals Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in dose escalation stage	DLTs will be evaluated from Day 1 (the day of the first dose) to Day 21 after first dose of study treatment in escalation stage. Number of DLTs will be used in dose ascending and descending decisions.	Day 1 to Day 21 after first dose (21 days)
Primary	Number of subjects with adverse events (AEs)	AEs will be characterized by type, seriousness, relationship to study treatment, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0) and timing.	From screening (Day -28 to Day -1) through up to 12 months or until disease progression
Secondary	Pharmacokinetic Assessments: Time to maximum plasma concentration (Tmax)	Blood and urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	PK Blood (Cycle 1 Day 1 and Cycle 1 Day 15; PK Urine (Cycle 1 Day 1) (each cycle is 21 days)
Secondary	Pharmacokinetic Assessments: Maximum concentration (Cmax)	Blood and urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	PK Blood (Cycle 1 Day 1 and Cycle 1 Day 15; PK Urine (Cycle 1 Day 1) (each cycle is 21 days)
Secondary	Pharmacokinetic Assessments: Elimination half-life (t1/2)	Blood and urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	PK Blood (Cycle 1 Day 1 and Cycle 1 Day 15; PK Urine (Cycle 1 Day 1) (each cycle is 21 days)
Secondary	Pharmacokinetic Assessments: Area under the concentration-time curve over time 0 to t (AUC0-t)	Blood and urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	PK Blood (Cycle 1 Day 1 and Cycle 1 Day 15; PK Urine (Cycle 1 Day 1) (each cycle is 21 days)
Secondary	Pharmacokinetic Assessments: Area under the concentration-time curve over time 0 to infinite (AUC0-inf)	Blood and urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	PK Blood (Cycle 1 Day 1 and Cycle 1 Day 15; PK Urine (Cycle 1 Day 1) (each cycle is 21 days)
Secondary	Pharmacokinetic Assessments: Accumulation ratio (Rac)	Blood and urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	PK Blood (Cycle 1 Day 1 and Cycle 1 Day 15; PK Urine (Cycle 1 Day 1) (each cycle is 21 days)
Secondary	Pharmacokinetic Assessments: Cumulative urinary excretion	Urine samples will be collected for PK analyses for subjects enrolled in dose escalation stage.	Cycle 1 Day 1 (each cycle is 21 days)
Secondary	Tumor Response	Tumor response measured by radiologic imaging techniques at baseline and throughout the study. The same radiologic imaging techniques for each respective patient will be used throughout. Tumor response will be assessed by investigator according to RECIST v1.1.	Screening until disease progression, initiation of a new anti-tumor therapy, death, loss to follow-up, withdrawal of consent, or meeting other end-of-study criteria (whichever occurs first) (Assessed up to 12 months).